PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0300644 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Yin Min Thu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmac…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Crizotinib, Drug Resistance, Neoplasm, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Mechanisms underlying primary and acquired resistance to MET tyrosine kinase inhibitors (TKIs) in managing non-small cell lung cancer remain unclear. In this study, we investigated the possible mechanisms acquired for crizotinib in MET -amplified lung carcinoma cell lines. Two MET -amplified lung cancer cell lines, EBC-1 and H1993, were established for acquired resistance to MET-TKI crizotinib and were functionally elucidated. Genomic and transcriptomic data were used to assess the factors contributing to the resistance mechanism, and the alterations hypothesized to confer resistance were validated. Multiple mechanisms underlie acquired resistance to crizotinib in MET -amplified lung cancer cell lines. In EBC-1-derived resistant cells, the overexpression of SERPINE1, the gene encoding plasminogen activator inhibitor-1 (PAI-1), mediated the drug resistance mechanism. Crizotinib resistance was addressed by combination therapy with a PAI-1 inhibitor and PAI-1 knockdown. Another mechanism of resistance in different subline cells of EBC-1 was evaluated as epithelial-to-mesenchymal transition with the upregulation of antiapoptotic proteins. In H1993-derived resistant cells, MEK inhibitors could be a potential therapeutic strategy for overcoming resistance with downstream mitogen-activated protein kinase pathway activation. In this study, we revealed the different mechanisms of acquired resistance to the MET inhibitor crizotinib with potential therapeutic application in patients with MET -amplified lung carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
- Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
- Department of Surgery, Division of Cardiovascular and Thoracic Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.
ORCID-Profile: Yin Min Thu, Ken Suzawa, Kazuhiko Shien, Mikio Okazaki, Seiichiro Sugimoto
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Thu, Y. M., Suzawa, K., Tomida, S., Ochi, K., Tsudaka, S., Takatsu, F., Date, K., Matsuda, N., Iwata, K., Nakata, K., Shien, K., Yamamoto, H., Okazaki, M., Sugimoto, S., & Toyooka, S. (2024). PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0300644
Vancouver
Thu YM, Suzawa K, Tomida S, Ochi K, Tsudaka S, Takatsu F, et al. PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer. PLOS ONE. 2024. doi:10.1371/journal.pone.0300644
BibTeX
@article{Thu2024,
author = {Thu, Yin Min and Suzawa, Ken and Tomida, Shuta and Ochi, Kosuke and Tsudaka, Shimpei and Takatsu, Fumiaki and Date, Keiichi and Matsuda, Naoki and Iwata, Kazuma and Nakata, Kentaro and Shien, Kazuhiko and Yamamoto, Hiromasa and Okazaki, Mikio and Sugimoto, Seiichiro and Toyooka, Shinichi},
title = {PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0300644}
}
EUVIMED